Biofrontera AG

Advanced notice of conference calls on half-year report of 2017

Business news for the stock market

Leverkusen (pta012/21.08.2017/10:10) - Biofrontera AG (ISIN: DE0006046113), the specialist for the treatment of sun-induced skin cancer, will be announcing its financial results for the six-month period ended June 30, 2017 on 31 August 2017.

Conference calls for shareholders and interested investors will be held on 31 August 2017 at the following times:

10.00am CEST (4.00am EDT) conference call in German:
Dial-in number: [phone]
Conference code: 95144584 #

2.00pm CEST (8.00am EDT) conference call in English:
Dial-in number Germany: [phone]
Dial-in number UK: [phone]
Dial-in number USA: [phone]
Dial-in number USA (New York): [phone]
Conference code: 53789711 #

Enquiries, please contact:

Biofrontera AG
Thomas Schaffer, Chief Financial Officer
[phone]
[e-mail]

IR Germany: Brainwell Asset Solutions
Jürgen Benker
[phone]

IR UK: Seton Services
Toni Vallen
[phone]

IR and PR US: The Ruth Group
IR: Tram Bui
[phone]

PR: Kirsten Thomas
[phone]

About Biofrontera:
Biofrontera AG is a biopharmaceutical company specializing in the development, sale and distribution of dermatological drugs and medical cosmetics. The Leverkusen, Germany-based company, which has approximately 100 employees worldwide, develops and distributes innovative products for the care, protection and treatment of the skin. Biofrontera's combination lead product is topical prescription drug Ameluz® and medical device BF-RhodoLED® for the photodynamic therapy (PDT) treatment of superficial skin cancer and its precursors. Ameluz® has been marketed in the EU since 2012 and in the U.S. since 2016. The Company also markets the Belixos® dermocosmetics series in the EU, which offers specialized care for damaged or diseased skin.

Biofrontera is the first German, founder-led pharmaceutical company to obtain both EU and U.S. approval for a medical drug it has developed itself. The Biofrontera Group was established in 1997 by current CEO, Prof. Dr. Hermann Lübbert, and is listed on the Frankfurt Stock Exchange (Prime Standard).

http://www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking statements concerning the business activities of Biofrontera AG. These forward-looking statements reflect the opinion of Biofrontera at the time of this communication and involve certain known and unknown risks. The actual results achieved by Biofrontera may differ significantly from future results or performances which are published in its forward-looking statements. Biofrontera assumes no responsibility to update its forward-looking statements.

(end)

emitter: Biofrontera AG
address: Hemmelrather Weg 201, 51377 Leverkusen
country: Germany
contact person: Investor & public relations
phone: [phone]
e-mail: [e-mail]
website: www.biofrontera.com

ISIN(s): DE0006046113 (share)
stock exchanges: regulated market in Frankfurt, Dusseldorf; free market in Stuttgart, free market in Munich; open market in Berlin, Tradegate

[ source: http://www.pressetext.com/news/20170821012 ]